Show simple item record

dc.contributor.authorPoonia, Bhawna
dc.contributor.authorKottilil, Shyam
dc.date.accessioned2020-10-23T14:26:14Z
dc.date.available2020-10-23T14:26:14Z
dc.date.issued2020-09-29
dc.identifier.urihttp://hdl.handle.net/10713/13915
dc.description.abstractCOVID-19 caused by SARS CoV2 emerged in China at the end of 2019 and soon become a pandemic. Since the virus is novel, pre-existing CoV2-specific immunity is not expected to exist in humans, although studies have shown presence of CoV2 cross-reactive T cells in unexposed individuals. Lack of effective immunity in most individuals along with high infectiousness of the virus has resulted in massive global public health emergency. Intense efforts are on to study viral pathogenesis and immune response to help guide prophylactic and therapeutic interventions as well as epidemiological assessments like transmission modeling. To develop an effective vaccine or biologic therapeutic, it is critical to understand the immune correlates of COVID-19 control. At the same time, whether immunity in recovered individuals is effective for preventing re-infection will be important for informing interventions like social distancing. Key questions that are being investigated regarding immune response in COVID-19 which will help these efforts include, investigations of immune response that distinguishes patients with severe versus mild infection or those that recover relative to those that succumb, durability of immunity in recovered patients and relevance of developed immunity in a cured patient for protection against re-infection as well as value of convalescent plasma from recovered patients as a potential therapeutic modality. This is a broad and rapidly evolving area and multiple reports on status of innate and adaptive immunity against SARS-CoV2 are emerging on a daily basis. While many questions remain unanswered for now, the purpose of this focused review is to summarize the current understanding regarding immune correlates of COVID-19 severity and resolution in order to assist researchers in the field to pursue new directions in prevention and control. © Copyright © 2020 Poonia and Kottilil.en_US
dc.description.sponsorshipNational Institute on Drug Abuseen_US
dc.description.urihttps://doi.org/10.3389/fimmu.2020.569611en_US
dc.language.isoenen_US
dc.publisherFrontiers Media S.A.en_US
dc.relation.ispartofFrontiers in Immunologyen_US
dc.subjectCOVID-19 B cellsen_US
dc.subjectCOVID-19 controlen_US
dc.subjectCOVID-19 immune therapyen_US
dc.subjectCOVID-19 vaccineen_US
dc.subjectimmune correlates of COVID-19en_US
dc.subjectSARS-CoV2 antibodiesen_US
dc.subjectSARS-CoV2 specific immunityen_US
dc.subjectSARS-CoV2 T cellsen_US
dc.titleImmune Correlates of COVID-19 Controlen_US
dc.typeArticleen_US
dc.identifier.doi10.3389/fimmu.2020.569611
dc.source.journaltitleFrontiers in Immunology
dc.source.volume11


This item appears in the following Collection(s)

Show simple item record